A 24-year-old female who has
primary generalised epilepsy and is on sodium valproate attends the antenatal
clinic for her first consultation. The registrar who sees her rings you up to
ask you for advice regarding the risk of teratogenecity of this drug. You
reply that the baby is at risk of developing:
